

Teneliximab

Cat. No.:	HY-P99321
CAS No.:	299423-37-3
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion ^[1] .
In Vitro	The effects of Teneliximab (Chi220, BMS-224819) are not mediated solely through deletion of CD20-bearing cells and that the combined therapy did not significantly impair established antiviral immunity ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Maria A Argiriadi, et al. CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019 Aug 5;20(1):29.
- [2]. Andrew B Adams, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol. 2005 Jan 1;174(1):542-50.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA